Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BMY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BMY and 80,000+ other tickers.
See exactly how BMY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BMY and 80,000+ other tickers.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial…
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bank of America is breaking with the Fed's wait-and-see approach and pushing for rate hikes now, which reshuffles the entire investing playbook. Four dividend-paying stocks across the sectors that quietly thrive when borrowing costs climb deserve a closer look.
Assetmark Inc. cut its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 14.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,837 shares of the biopharmaceutical company's stock after selling 24,825 shares during the period. Assetmark Inc.'s
Andra AP fonden cut its stake in Bristol Myers Squibb Company (NYSE: BMY) by 51.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 332,662 shares of the biopharmaceutical company's stock after selling 348,938 shares during the period. Andra
Bessemer Group Inc. boosted its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 19.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,632 shares of the biopharmaceutical company's stock after purchasing an additional 11,584 shares during the quarter.